LUND, Sweden, May 12, 2020 /PRNewswire/ -- Immunovia invites you to a teleconference (in English) for all stakeholders and media on Wednesday, May 13, 2020 at 16:30 CET. Mats Grahn, CEO will present an update on the company's COVID-19 response as well as an update on the activities in preparation for the launch of IMMray PanCan-d and the prospective studies followed by a Q&A session.
Participants will need to pre-register for the call via the following link: Register Here
Once pre-registered, each participant will then receive a personal user code to access the live call.
For the live call, please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code 2514192 to the operator as well as your user code obtained from pre-registration:
Conference Dial in numbers:
Sweden: +46-(0)-8-5051-0086
United States: +1-646-843-4609
Austria: +43-(0)-1928-4054
Denmark: +45-3272-9274
Finland: +358-9-2319-5436
France: +33-(0)-4-2684-0314
Germany: +49-(0)-511-9361-2555
Netherlands: +31-(0)-20-7948428
Norway: +47-2-156-3319
Spain: +34-91-787-0778
UK (Standard International Access): +44-(0)-20-3003-2701
Conference Code: 2514192
User Code: obtained from pre-registration (Register Here)
Immunovia Webcast: https://channel.royalcast.com/webcast/immunovia/20200513_1/
For more information, please contact:
Julie Silber, Director of Investor Relations,
Immunovia Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
There will be an MP3-file available at Immunovia's webpage under Investors/Audio-Gallery (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
CONTACT:
Immunovia AB
Medicon Village Scheelevägen 2 SE-223 81 Lund
+46 46 275 60 00
http://www.immunovia.com
info@immunovia.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-immunovia-s-update--3-on-covid-19-company-response,c3110034
The following files are available for download:
https://mb.cision.com/Main/13121/3110034/1246532.pdf | Release |
